By Sheeba M. | May 14, 2026
Cannabis Earnings Season: What to Watch This Quarter
Cannabis earnings season is upon us, and investors should focus on three key metrics: gross margin compression, SG&A efficiency, and cash flow burn. The narrative has shifted from “growth at all costs” to “profitability under pressure.”
Large cap players like Curaleaf and Green Thumb will report results that show the real state of cannabis retail: slowing demand in mature markets, price competition intensifying, and regulatory compliance costs rising. The question is whether operational leverage and scale can overcome these headwinds.
Metrics That Matter
Adjusted EBITDA Margin: Cannabis investors obsess over EBITDA because it approximates cash generation. As price war dynamics persist, companies that maintain 25-30% adjusted EBITDA margins while growing revenue are the ones worth holding. Watch for guidance on margin outlook—if it’s negative, that’s a warning.
Store-Level Economics: Trulieve’s same-store sales (SSS) growth (or lack thereof) will be the bellwether for retail saturation. If SSS turns negative, it signals the market is cannibalizing itself.
Cash Position & Debt: Many MSOs refinanced at higher rates in 2024-2025. Companies that locked in fixed rates or paid down debt during profitable periods have flexibility. Those with rising debt service costs face pressure on free cash flow.
Forward Guidance
The most important signal will be management’s tone on federal legalization impact. If execs sound bullish on CBD hemp-derived products or optimistic on de-scheduling timelines, it could signal confidence in margin expansion. Verano and Columbia Care will likely emphasize operational efficiency—a proxy for believing margins will compress further before legalization creates new revenue pools.
Sources
- SEC EDGAR Database — 10-Q and 8-K filings
- MJFreeway Earnings Calendar — Cannabis company earnings dates
- Benzinga Cannabis — Market analysis and sentiment
Track cannabis stocks with the Weedstock Real-Time Tracker